A phase i study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 4, 2012, Pages 559-565

  Nokihara, Hiroshi ^a   Yamamoto, Noboru ^a   Yamada, Yasuhide ^a   Yamada, Kazuhiko ^a   Hirata, Taizo ^a   Goto, Yasushi ^a   Tanioka, Maki ^a   Ikeda, Yoko ^b   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b Research and Development Division   (Japan)

Author keywords

BMS 690514; Phase I trial; Solid tumor; Tyrosine kinase inhibitor

Indexed keywords

BMS 690514; COLLAGEN TYPE 4; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; K RAS PROTEIN; MITOMYCIN C; NITROSOUREA; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ACNE; ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COLON CANCER; COLON SURGERY; DIARRHEA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EGFR GENE; FATIGUE; FEMALE; FIBRINOGEN BLOOD LEVEL; GENE; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; JAPANESE; LEIOMYOSARCOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS POTENTIAL; MUSCLE RESECTION; ONCOGENE K RAS; OPEN STUDY; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PRURITUS; REPEATED DRUG DOSE; SIDE EFFECT; STOMATITIS; THYMECTOMY; THYMUS CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; PYRROLES; TRIAZINES;

EID: 84867577176     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1932-9     Document Type: Article

References (23)

1. Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capó A, Germonpré P, Eberhardt WE, Stockman PK, Kennedy SJ, Ranson M (2009) Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 27:2523- 2529
2. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J et al (2011) Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 29:1059-1066
3. Shahi PK, Lovelle AS, Manga GP (2009) Tumoral angiogenesis and breast cancer. Clin Transl Oncol 11:138-142
4. Banerjee S, Dowsett M, Ashworth A, Banerjee S, Dowsett M, Ashworth A, Martin LA (2007) Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 4:536-550
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
6. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257
7. Reck M, Crino L (2009) Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer 63:1-9
8. de La Motte RT, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, Lazar V, Dessen P, Harper F et al (2007) A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 67:6253-6262
9. Wong TW, Ayers M, Emanuel S, Fargnoli J, Harbison C, Lee F, Oppenheimer S, Yu C, Krishnan B, Zhang H, et al. (2007) Inhibition of EGFR/HER2 signaling in tumor cells and VEGFR2 activity in tumor endothelium contribute to the preclinical antitumor activity of BMS-690514. In: 98th AACR annual meeting (meeting abstract): 4007, Los Angeles, C.A.
10. Bahleda R, Soria J, Harbison C, Park J, Felip E, Hanna N, Laurie SA, Armand J, Shepherd FA, Herbst R (2009) Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. J Clin Oncol 27:15S, Abstract 8098. (Meeting abstract)
11. Boxenbaum H, Battle M (1995) Effective half-life in clinical pharmacology. J Clin Pharmacol 35:763-766
12. Tabernero J (2007) The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5:203-220
13. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9:117-123
14. Verheul HM, Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7:475-485
15. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579-591
16. Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris AH (2009) Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 9:82
17. Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT (2011) Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing antiepileptic drugs and standard radiation and temozolomide. J Neurooncol 103:325-332
18. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB et al (2007) Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:2369-2376
19. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:82-95
20. Pena C, Lathia C, Shan M, Escudier B, Bukowski RM (2010) Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 16:4853-4863
21. Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, Bordogna W, Ottesen LH, Heymach JV (2010) Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non- small cell lung cancer patients treated with pazopanib. Cancer Res 70:2171-2179
22. Mukohara T, Nakajima H, Mukai H, Nagai S, Itoh K, Umeyama Y, Hashimoto J, Minami H (2010) Effect of axitinib (AG- 013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci 101:963-968
23. Chow PL, Ho CP, Kukral D, Henley BJ, Wong TW, Krishnan BS (2007) Evaluation of chemotherapeutic compound BMS-690514 in L2987 xenograph mouse model using microPET imaging. In: 98th AACR annual meeting (Meeting abstract): 4009, Los Angeles, C.A.